Details of the Drug

General Information of Drug (ID: DMAC130)

Drug Name
Inotuzumab ozogamicin
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1], [2]
Acute lymphocytic leukaemia 2B33.3 Approved [3]
Drug Type
Antibody
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 308 mcg/L [4]
Clearance
The clearance of drug is 0.0333 L/h [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.3 days [4]
Vd
The volume of distribution (Vd) of drug is 12 L [4]
Cross-matching ID
DrugBank ID
DB05889
TTD ID
D00QEP

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Inotuzumab ozogamicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Ivosidenib. Acute myeloid leukaemia [2A60] [16]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Midostaurin. Acute myeloid leukaemia [2A60] [17]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Oliceridine. Acute pain [MG31] [17]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Inotuzumab ozogamicin and Ivabradine. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Levalbuterol. Asthma [CA23] [19]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Inotuzumab ozogamicin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [20]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Eribulin. Breast cancer [2C60-2C6Y] [17]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Bosutinib. Breast cancer [2C60-2C6Y] [17]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [17]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [21]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Inotuzumab ozogamicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [19]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Pasireotide. Cushing syndrome [5A70] [22]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Osilodrostat. Cushing syndrome [5A70] [17]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Deutetrabenazine. Dystonic disorder [8A02] [23]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Ingrezza. Dystonic disorder [8A02] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Inotuzumab ozogamicin and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Inotuzumab ozogamicin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [24]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [17]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [25]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Inotuzumab ozogamicin and BMS-201038. Hyper-lipoproteinaemia [5C80] [26]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Inotuzumab ozogamicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Inotuzumab ozogamicin and Denosumab. Low bone mass disorder [FB83] [27]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Crizotinib. Lung cancer [2C25] [28]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Ceritinib. Lung cancer [2C25] [22]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Osimertinib. Lung cancer [2C25] [29]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Selpercatinib. Lung cancer [2C25] [17]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Lumefantrine. Malaria [1F40-1F45] [30]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Inotuzumab ozogamicin and Idelalisib. Mature B-cell leukaemia [2A82] [31]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Vemurafenib. Melanoma [2C30] [22]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and LGX818. Melanoma [2C30] [17]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Tecfidera. Multiple sclerosis [8A40] [32]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Inotuzumab ozogamicin and Siponimod. Multiple sclerosis [8A40] [30]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Inotuzumab ozogamicin and Fingolimod. Multiple sclerosis [8A40] [33]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Ocrelizumab. Multiple sclerosis [8A40] [34]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Ozanimod. Multiple sclerosis [8A40] [17]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Romidepsin. Mycosis fungoides [2B01] [17]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Entrectinib. Non-small cell lung cancer [2C25] [30]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Rucaparib. Ovarian cancer [2C73] [17]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Triclabendazole. Parasitic worm infestation [1F90] [17]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [35]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Lefamulin. Pneumonia [CA40] [36]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Degarelix. Prostate cancer [2C82] [17]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Enzalutamide. Prostate cancer [2C82] [17]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Relugolix. Prostate cancer [2C82] [17]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Canakinumab. Rheumatoid arthritis [FA20] [37]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Rilonacept. Rheumatoid arthritis [FA20] [37]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Inotuzumab ozogamicin and Golimumab. Rheumatoid arthritis [FA20] [38]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Amisulpride. Schizophrenia [6A20] [39]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Asenapine. Schizophrenia [6A20] [22]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Inotuzumab ozogamicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [40]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [17]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Pitolisant. Somnolence [MG42] [17]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Lenvatinib. Thyroid cancer [2D10] [17]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Cabozantinib. Thyroid cancer [2D10] [17]
⏷ Show the Full List of 59 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8266).
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017171)
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 European Medicines Agency (EMA): BESPONSA Summary of Product Characteristics
5 Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
6 Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
7 Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
8 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
9 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
10 Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
11 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
12 ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
13 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
14 ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
15 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
16 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
21 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
22 Canadian Pharmacists Association.
23 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
24 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
25 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
26 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
27 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
28 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
29 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30 Cerner Multum, Inc. "Australian Product Information.".
31 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
32 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
33 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
34 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
35 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
36 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
37 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
38 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
39 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
40 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]